Wondering how to use Actemra in a sentence? Below are 2 example sentences from authentic English texts. .
Actemra in a sentence
Context around Actemra
- Average sentence length in these examples: 30.5 words
- Position in the sentence: 1 start, 0 middle, 1 end
- Sentence types: 2 statements, 0 questions, 0 exclamations
Corpus analysis for Actemra
- In this selection, "actemra" usually appears near the start of the sentence. The average example has 30.5 words, and this corpus slice is mostly made up of statements.
- Around the word, roactemra and tocilizumab stand out and add context to how "actemra" is used.
- Recognizable usage signals include actemra roactemra was and antibodies like actemra tocilizumab and. That gives this page its own corpus information beyond isolated example sentences.
- By corpus frequency, "actemra" sits close to words such as aabc, aacr and aacsb, which helps place it inside the broader word index.
Example types with actemra
The same corpus examples are grouped by length and sentence type, making it easier to see the contexts in which the word appears:
Several drugs that target inflammatory cytokines are in clinical development for Covid-19, including anti-IL-6 monoclonal antibodies like Actemra (tocilizumab) and Regeneron Pharmaceuticals Kevzara (sarilumab). (27 words)
Actemra/RoActemra was the first approved anti-IL-6 receptor biologic available in both intravenous (IV) and subcutaneous (SC) formulations for the treatment of adult patients with moderate-to-severe active rheumatoid arthritis (RA). (34 words)
Actemra/RoActemra was the first approved anti-IL-6 receptor biologic available in both intravenous (IV) and subcutaneous (SC) formulations for the treatment of adult patients with moderate-to-severe active rheumatoid arthritis (RA). (34 words)
Several drugs that target inflammatory cytokines are in clinical development for Covid-19, including anti-IL-6 monoclonal antibodies like Actemra (tocilizumab) and Regeneron Pharmaceuticals Kevzara (sarilumab). (27 words)
Example sentences (2)
Actemra/RoActemra was the first approved anti-IL-6 receptor biologic available in both intravenous (IV) and subcutaneous (SC) formulations for the treatment of adult patients with moderate-to-severe active rheumatoid arthritis (RA).
Several drugs that target inflammatory cytokines are in clinical development for Covid-19, including anti-IL-6 monoclonal antibodies like Actemra (tocilizumab) and Regeneron Pharmaceuticals Kevzara (sarilumab).